To investigate the morphologic appearance of macular edema and functional changes in Behcet’s disease before and after intravitreal bevacizumab (Avastin) injection.

15 patients with Behcet’s disease and bilateral macular edema and mean age of 30.6±7.4 years were included in this prospective, single masked case series. 1.25 mg/0.05 ml bevacizumab was injected in the more severely involved eye as the case by mean 3.3 injections per 6 months and other eyes were considered as the control.Patients were followed up for at least 6 months by ophthalmologic exam, optical coherence tomography (OCT) and fluorescein angiography. IVB was repeated if the thickness exceeded 300 µm in OCT in the previously injected eye.

Bevacizumab was injected in the cases by a mean 3.3 injections per 6 months. The mean central foveal thickness was 375.37±132.12 in the case group and 307.22±84.50 in the control group. The mean VA with LOGMAR scale was 0.6±0.3 for IVB group and 0.4±0.4 for control group in the first visit. The improvement of VA during 6 months was not significant in both groups. Avastin provided a non-statistically improvement in macular edema in the case group during the follow up period at 6th month (P=0.083). No statistically significant improvement of visual acuity and fluorescein angiographic findings were observed in this study. There was a direct association between the presence of cysts and leakage extend (P= 0.022). An association between cystic changes with visual acuity and vascular leakage (P= 0.026) was detected.

In this study, no significant improvement was observed in VA, OCT and FA findings after intravitreal injection of Avastin.